Video

Common Causes for Non-Adherence to Endocrine Therapy

Dawn Hershman, MD, MS, discusses various reasons for non-adherence to endocrine therapy in breast cancer patients. This video was filmed December 13 at the 2019 San Antonio Breast Cancer Symposium.

Dawn Hershman, MD, MS: So non-adherence to endocrine therapy is really common; I think a lot more common than we initially realized from clinical trials. I think [it’s] because people assumed that if somebody was taking a medicine to prevent their cancer from coming back, they would of course be compliant. But medication non-adherence or non-compliance is incredibly common, both in cancer and in non-cancer—hypertension, anti-HIV, antibiotics. It’s very hard for people to take medications for a long period of time, and part of the reason why patients are non-compliant is related to behavioral factors and remembering to take their medication, but also knowing how important the medication is. It’s related to financial factors such as the cost, how much out of pocket cost they have, how many financial resources they have in addition to the cost, their insurance. But most commonly it’s related to side effects, so patients with more side effects are often less likely to be adherent over the course of their therapy.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com